ClinicalTrials.Veeva

Menu

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

ViiV Healthcare logo

ViiV Healthcare

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: Maraviroc
Drug: Maraviroc + Fosamprenavir/ritonavir
Drug: Fosamprenavir/ritonavir

Study type

Interventional

Funder types

Industry

Identifiers

NCT01290211
A4001103

Details and patient eligibility

About

This is will be an open-label, fixed-sequence, multiple dose crossover study in 2 cohorts of 14 healthy male and/or female subjects, to estimate the effect of maraviroc on the pharmacokinetics of amprenavir and ritonavir and fosamprenavir/ritonavir on the pharmacokinetics of maraviroc.

Enrollment

28 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.
  • Total body weight >50 kg (110 lbs).

Exclusion criteria

  • History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
  • Positive result for HIV, Hepatitis B or Hepatitis C virus.
  • Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
  • Known hypersensitivity or history of allergy to sulfonamides.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

28 participants in 2 patient groups

Cohort 1
Experimental group
Description:
Twice daily regimen
Treatment:
Drug: Fosamprenavir/ritonavir
Drug: Maraviroc
Drug: Maraviroc + Fosamprenavir/ritonavir
Drug: Maraviroc
Drug: Fosamprenavir/ritonavir
Drug: Maraviroc + Fosamprenavir/ritonavir
Cohort 2
Experimental group
Description:
Once daily regimen
Treatment:
Drug: Fosamprenavir/ritonavir
Drug: Maraviroc
Drug: Maraviroc + Fosamprenavir/ritonavir
Drug: Maraviroc
Drug: Fosamprenavir/ritonavir
Drug: Maraviroc + Fosamprenavir/ritonavir

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems